Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Sonelokimab Phase 3 Results Expected
Sonelokimab • Hidradenitis Suppurativa
Target Indication
Hidradenitis Suppurativa
Clinical Trial
Last updated: 12/4/2025
MLTX
MoonLake Immunotherapeutics
Arthritis, Psoriatic